Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases (IBD): Real World Results from the International Organization for the study of IBD.
Journal article
Vieujean S. et al, (2023), Journal of Crohn's & colitis
Development of the Escalation of Therapy or Intervention (ETI) Calculator for Patients with Ulcerative Colitis Using ePROMs
Journal article
Matini L. et al, (2023), Journal of Crohn's and Colitis
An Extremes of Phenotype Approach Confirms Significant Genetic Heterogeneity in Patients with Ulcerative Colitis.
Journal article
Mortlock S. et al, (2023), Journal of Crohn's & colitis, 17, 277 - 288
Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response.
Journal article
Adams A. et al, (2023), Gut, 72, 433 - 442
Generalised urticaria and angioedema complicating switch back from subcutaneous to intravenous vedolizumab therapy.
Journal article
Chauhan D. et al, (2023), Frontline gastroenterology, 14, 432 - 434
Patient-reported Outcomes: the ICHOM Standard Set for Inflammatory Bowel Disease in Real-life Practice Helps Quantify Deficits in Current Care
Conference paper
Wong D. et al, (2022), Journal of Crohn's and Colitis, 16, 1874 - 1881
Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children.
Journal article
Liu Z. et al, (2022), Journal of Crohn's & colitis, 16, 1835 - 1844
Novel inflammatory bowel disease (IBD) specific electronic medical record allows scalable auditing of IBD severity, therapy and complications to show the current unmet need in IBD care.
Journal article
Barnes A. et al, (2022), Intestinal research, 20, 506 - 508
A MULTICENTRE EXPERIENCE OF HOME FAECAL CALPROTECTIN (CALPROSMARTTM) TESTING DURING THE COVID-19 PANDEMIC
Conference paper
Al-Hillawi L. et al, (2022), GUT, 71, A37 - A37
Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study.
Journal article
Honap S. et al, (2022), Frontline gastroenterology, 13, 517 - 523
Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.
Journal article
McGregor CG. et al, (2021), Gut, 70, 2398 - 2400
Stress-related consequences of the coronavirus disease 2019 pandemic on symptoms of Crohn's disease.
Journal article
Goodday SM. et al, (2021), European journal of gastroenterology & hepatology, 33, 1511 - 1516
Using item response theory (IRT) to improve the efficiency of the Simple Clinical Colitis Activity Index (SCCAI) for patients with ulcerative colitis
Journal article
Walsh A. et al, (2021), BMC Gastroenterology, 21
A Pilot Study on Automatic Three-Dimensional Quantification of Barrett’s Esophagus for Risk Stratification and Therapy Monitoring
Journal article
Ali S. et al, (2021), Gastroenterology, 161, 865 - 878.e8
Author Correction: A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals
Journal article
Demetriou P. et al, (2021), Nature Immunology, 22, 99 - 99
CHANGING OUTCOMES IN ACUTE SEVERE ULCERATIVE COLITIS AT OXFORD IN LAST SEVEN DECADES
Conference paper
Gupta V. et al, (2021), GUT, 70, A97 - A97
FAECAL MICROBIOTA TRANSPLANT FOR REFRACTORY CHECKPOINT INHIBITOR IMMUNOTHERAPY-RELATED COLITIS
Conference paper
Cheung V. et al, (2021), GUT, 70, A89 - A89
PREDICTION OF OUTCOME IN ACUTE SEVERE ULCERATIVE COLITIS - COMPARISON OF CLINICAL AND ENDOSCOPIC INDICES
Conference paper
Gupta V. et al, (2021), GUT, 70, A96 - A97
REAL WORLD EFFECTIVENESS OF USTEKINUMAB FOR REFRACTORY CROHN'S DISEASE: A REGIONAL EXPERIENCE
Conference paper
Mcgregor C. et al, (2021), GUT, 70, A108 - A108